Below you'll find a list of all posts that have been tagged as “Kyowa Kirin International”
Borders-based specialty pharmaceutical company, Kyowa Kirin International plc (KKI), announces that it is to expand its headquarters facility in Galashiels, Scotland, to accommodate the growth of the business. The news comes as KKI reports record turnover of £251m for 2016, growth of 13% over 2015 revenues of £222m. KKI (formerly known as ProStrakan) is a wholly-owned subsidiary of Japan-based Kyowa …
Ultragenyx and Kyowa Kirin International Announce Marketing Authorisation Application for KRN23 Filed and Accepted for Review by European Medicines Agency.
ProStrakan, the Scotland-based specialty pharmaceutical company, announces today (18th April, 2016) that it is rebranding as Kyowa Kirin from today’s date.
ProStrakan was acquired by Tokyo-based Kyowa Hakko Kirin Co. Ltd…
ProStrakan Group, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and AstraZeneca today announced that they have entered into an agreement for ProStrakan to acquire the rights to Moventig® (naloxegol) in the European Union (EU)…
Spreng Thomson: Intelligent Creative Communications
Spreng Thomson is committed to Fair Work, by ensuring that our people have an effective voice, by investing in their development and by not using zero hours contracts.
+44(0)141 548 5191
[email protected]
The Herald Building,
155 Albion Street,
Glasgow G1 1RU, UK
© 2024 Spreng Thomson Limited.
Registered in Scotland No. 173454
